{
  "trial_id": "NCT00817739",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Histologically confirmed metastatic cancer of the prostate (stage D2 or Tx Nx M1 \u2260 M1a) with measurable bone or visceral (lung, liver, etc.) metastases",
      "label": "met",
      "evidence": "radiographic conformation was necessary in the event of a questionable bone scan detection in conjunction with only slightly elevated PSA levels [at least 20 ng/mL or less than or equal to 50 ng/mL]"
    },
    {
      "criterion": "Metastatic cancer of the prostate requiring first-line therapy",
      "label": "met",
      "evidence": ""
    },
    {
      "criterion": "Pre-assessment PSA 5-fold or higher than the standard level set by the central laboratory, that is, PSA greater than or equal to (\u2265) 20 ng/mL as quantitated by the Hybritech radioimmunoassay (normal is less than [<] 4 ng/mL)",
      "label": "met",
      "evidence": ""
    },
    {
      "criterion": "ECOG performance status of no more than 2",
      "label": "met",
      "evidence": ""
    },
    {
      "criterion": "Normal testosterone levels according to the central laboratory standards",
      "label": "met",
      "evidence": ""
    },
    {
      "criterion": "Aspartate transaminase (AST) and alanine transaminase (ALT) < 2.25-fold higher than the standard levels set by the central laboratory (except when liver metastases were present)",
      "label": "met",
      "evidence": ""
    },
    {
      "criterion": "Anticipated life expectancy greater than 9 months",
      "label": "met",
      "evidence": ""
    },
    {
      "criterion": "Criteria for Continuous or Intermittent Treatment Phase - Subjects who meet the pre-assessment criteria and who has PSA < 4 ng/mL after 6 months of induction therapy",
      "label": "met",
      "evidence": ""
    }
  ],
  "exclusion": [
    {
      "criterion": "Subject refuse to sign the informed consent form or is likely to be uncooperative or not to comply with the obligations set out in the study protocol",
      "label": "triggers",
      "evidence": ""
    },
    {
      "criterion": "Subject has received prior hormonal (and neoadjuvant) treatment prompting medical castration (estrogens, hormone-releasing hormone agonists, androgens) or has undergone surgical castration",
      "label": "triggers",
      "evidence": ""
    }
  ],
  "notes": "",
  "_meta": {
    "topic_id": "60",
    "trial_id": "NCT00817739",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}